Correction to ‘Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study’

Documents similaires

• Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
  par: C. Tziotzios, et autres
  Publié: (2025)
• Real‐world efficacy and safety of ritlecitinib in alopecia areata: A single‐centre experience
  par: Youyu Sheng, et autres
  Publié: (2025)
• SALT score distribution with ritlecitinib treatment up to 24 months in alopecia areata
  par: Ziad Reguiai, et autres
  Publié: (2025)
• Strong efficacy of ritlecitinib 50 mg and baricitinib 4 mg in alopecia areata, but further research needed to establish superiority
  par: David Saceda‐Corralo, et autres
  Publié: (2025)
• Alopecia areata and ritlecitinib: Unravelling response trajectories
  par: Julien Seneschal
  Publié: (2025)